Clinical Trial Detail

NCT ID NCT03322566
Title A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Paclitaxel + Pembrolizumab

Epacadostat + Pembrolizumab

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pemetrexed Disodium

Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab

Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium

Age Groups: senior adult

Additional content available in CKB BOOST